Video Library

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Continuing Immunotherapy Beyond Progression-In Which Patients Is This Appropriate

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses BRAF V600E As A Target In Advanced Non-Small Cell Lung Cancer

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses current standards for Molecular Testing At Initial Diagnosis Of Advanced Non-Small Cell Lung Cancer (NSCLC).

We are pleased to have GRACE’s Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute in Seattle, Washington, and President and CEO of GRACE bring 2017 updates to our Lung Cancer Video Library. In this latest video, Dr. West discusses advances in NSCLC – Timing Of

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses Novel Therapies In Small Cell Lung Cancer (SCLC): Lurbinectedin.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses evolving options in first line treatment of ALK-Positive non-small cell lung cancer (NSCLC).

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer NSCLC.

Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses the topic of lung cancer and that there is an entire spectrum of different kinds of cancers that have started inside the lungs. Small cell lung cancers behave very differently than non-small cell lung cancer. Basics of Small Cell

Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.

Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.